Keymed Biosciences (HKSE:02162) Marketable Securities : HK$1,854.8 Mil (As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Keymed Biosciences Marketable Securities?

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Keymed Biosciences's Marketable Securities for the quarter that ended in Dec. 2024 was HK$1,854.8 Mil.

Keymed Biosciences's annual Marketable Securities declined from Dec. 2022 (HK$2,871.4 Mil) to Dec. 2023 (HK$2,043.4 Mil) and declined from Dec. 2023 (HK$2,043.4 Mil) to Dec. 2024 (HK$1,854.8 Mil).

Keymed Biosciences Marketable Securities Historical Data

The historical data trend for Keymed Biosciences's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Keymed Biosciences Marketable Securities Chart

Keymed Biosciences Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Marketable Securities

Get a 7-Day Free Trial

183.35

2,453.78

2,871.36

2,043.35

1,854.76

Keymed Biosciences Semi-Annual Data
	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Marketable Securities	Get a 7-Day Free Trial						2,871.36	2,038.32	2,043.35	2,009.73	1,854.76

Keymed Biosciences Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Keymed Biosciences (HKSE:02162) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Keymed Biosciences Marketable Securities Related Terms

Thank you for viewing the detailed overview of Keymed Biosciences's Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Keymed Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Keymed Biosciences Inc (HKSE:02162) » Definitions » Marketable Securities

Comparable Companies

Traded in Other Exchanges

64Z:Germany

Address

No. 18 BioTown Middle Road, Building D2, Tianfu International BioTown, Chengdu, Sichuan, CHN, 610219

Website

https://www.keymedbio.com

Keymed Biosciences Inc is a biotechnology company with multiple clinical-stage assets. The company is focused on the in-house discovery and development of biological therapies that address large underserved medical needs in the autoimmune and oncology therapeutic areas. Its clinical-stage drug candidates include CM310, CM326, CM313, and CM336 among others. The company is engaged in biopharmaceutical research and development, which is regarded as a single reportable segment. Geographically, it generates a majority of its revenue from overseas markets and the rest from Mainland China.

Executives

Chen Bo	2201 Interest of corporation controlled by you
Eagle Hero Management Limited	2101 Beneficial owner
Trident Trust Company (hk) Limited	2301 Trustee
Moonshot Holdings Limited	2101 Beneficial owner
Hh Kny Holdings Limited
Hillhouse Investment Management, Ltd.
Boyu Capital Group Holdings Ltd
Xyxy Holdings Ltd.
Tong Xiaomeng

Keymed Biosciences Headlines

No Headlines